Ulysses® VR Upper Limb Therapy System is clinically designed and research based

Ulysses® is now available in Australia (included in the ARTG, No. 402309) and the United Kingdom (UKCA marked) for acquiring and enhancing skills for improving overall functional upper-limb mobility

Evaluated in a clinical setting

An independent, TGA registered¹ clinical trial conducted by qualified occupational therapists and physiotherapists at the University of Newcastle Research Centre in Tamworth, New South Wales, Australia evaluated the efficacy, engagement, comfort and adverse events when using a VR headset with Ulysses software.
Five participants completed a total of 15 sessions each using the Ulysses system over the course of the 5-week study.
The study’s primary objective was functional performance of the upper limb. Pre and post assessments were performed to measure each participant’s functional improvement using the Motor Assessment Scale and Fugl Meyer Scale.
Secondary outcomes related to the participant’s level of engagement, comfortability and motivation to continue using the system were collected in an exit survey at the conclusion of the trial.
Participants ranged in age from 50-78 and had suffered a haemorrhagic or ischaemic stroke.

Time since the stroke ranged from 18 months to 17 years.

Cognitive capacity ranged from significant to mild impairment (as measured on the Montreal Cognitive Assessment Scale from 11 to 25).
3 out of 5 participants demonstrated improved functional mobility as measured by the Motor Assessment Scale.

4 out of 5 participants showed improved functional mobility as measured by the Fugl Meyer Scale.
Participants ranged in age from 50-78 and had suffered a haemorrhagic or ischaemic stroke.

Time since the stroke ranged from 18 months to 17 years.

Cognitive capacity ranged from significant to mild impairment (as measured on the Montreal Cognitive Assessment Scale from 11 to 25).
3 out of 5 participants demonstrated improved functional mobility as measured by the Motor Assessment Scale.

4 out of 5 participants showed improved functional mobility as measured by the Fugl Meyer Scale.

Rated highly for comfort, engagement, and motivation.

On the scale of likeability, participants rated the Ulysses system an average of 80 out of 100.

The system was also rated on comfortability, where an average score of 79 out of 100 was recorded, with only a small number of cases reporting mild discomfort from wearing the headset and being in a VR environment.
All participants responded positively when asked if they would like to continue using the Ulysses system, providing a 76 out of 100 average rating.

Request a demo

One of our team members will respond to your enquiry shortly

Anshul Dayal

Co-Founder & CEO

Anshul has over 10 years experience in leading large technical teams in creating leading edge Hollywood content and software, including being a part of the Academy Award winning team to work on blockbuster film, Happy Feet.

Stephanie Ho

Neuromersiv Ambassador

After surviving a severe stroke at 22 years of age, Stephanie has committed her life to improve the healthcare system and easing the burden for other survivors. She currently serves as an Executive Board Member for NSW Agency for Clinical Innovation and is a regular keynote speaker on the topic of stroke and the impact of rehabilitation from a consumer perspective. Stephanie was awarded for her work in 2019 by the National Stroke Foundation.

Dr Jodie Marquez

Clinical & Research

Jodie is a physiotherapist with 20 years of experience in neuro-rehabilitation. She currently serves as Senior Lecturer at the University of Newcastle and has served as Chief Investigator on a number of funded clinical trial studies.

Professor Michael Nilsson

Rehabilitation Innovation

Michael is the Director of the Centre for Rehab Innovations and Global Innovation Chair of Rehabilitation Medicine at the University of Newcastle. As a senior translational researcher, clinician and leader in Rehabilitation Medicine, he recently established CRI together with an interdisciplinary team of leading researchers and clinicians. CRI engages with industry and public and private healthcare to develop technology-supported solutions for individually-tailored health and rehabilitation programs.

Warren Bingham

Commercialisation & Strategy

Warren is the General Manager of Cicada MedLab and the founder and Executive Chairman of MedTech International. As part of the global executive team to introduce PillCam® to the world, he was instrumental in the company going from startup in 2000 to being sold in 2014 for $1 billion.

Oliver Morton-Evans

Co-Founder & COO

Oliver has 7 years experience in design and project management having run visual effects & VR production studio, pic4 over this time. Prior to this, Oliver served as a digital media producer and designer for global children’s entertainment brand, The Wiggles.